Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the Auvergne Rhone-Alpes Region (AuRA) (VISIMAT)
Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the AuRA Region
Maternal mental health in the postpartum period is a major public health issue in France. The 2021 National Perinatal Survey highlights high prevalence rates of mental health disorders among mothers, with 27.6% experiencing anxiety disorders, 16.7% experiencing depressive disorders and 5.4% having suicidal thoughts. Between 2016 and 2018, suicide was also the leading cause of maternal mortality in the year following childbirth, underscoring the severity and frequency of these disorders. In response, international guidelines, notably those of the World health Organisation (WHO), as well as national policies such as the 'First 1,000 Days' strategy, emphasise the importance of early, enhanced and individualised postnatal support. In France, this postpartum care tends to be structured around the Early Postnatal Interview and the recommended use of validated screening tools such as the Edinburgh Postnatal Depression Scale (EPDS).
However, the quality of postpartum care depends not only on screening and clinical follow-up, but also on organisational and environmental factors. Among these, the arrangements for maternity ward visits constitute a potential determinant of patients' experiences, likely to influence both their mental state, their rest, the establishment of breastfeeding and, indirectly, the health of the newborn. The exceptional measures implemented during the Covid-19 pandemic, notably the restriction of visits, have shown generally favourable effects, with improved satisfaction among patients and healthcare staff, better conditions for rest, facilitation of breastfeeding and a perceived improvement in working conditions.
However, these data were collected in an exceptional health context, which may introduce biases linked to the social, emotional and organisational constraints specific to this period. Their extrapolation to routine practice therefore remains uncertain. Furthermore, in the absence of specific national guidelines governing maternity ward visits, the current regulatory framework remains unclear and practices vary between institutions, often relying on local decisions that have not been scientifically evaluated.
Against this backdrop, the VISIMAT study aims to characterise maternity ward visiting arrangements outside of any exceptional circumstances and to assess their impact on the health of mothers and newborns, as well as on healthcare workers' working conditions. Its aim is to provide a scientific basis to inform the development of standardised recommendations and prevention messages.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Marion Beucher, PhD
- 電話番号:+33 +33450637032
- メール:mbeucher@ch-annecygenevois.fr
研究場所
-
-
Auvergne-Rhône-Alpes
-
Épagny、Auvergne-Rhône-Alpes、フランス、74370
- CH Annecy Genevois
-
コンタクト:
- Marion Beucher, PhD
- 電話番号:+33 +33450637032
- メール:mbeucher@ch-annecygenevois.fr
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adult female patient (aged 18 or over),
- Female patient admitted to the maternity ward with her newborn baby or babies,
- Length of stay in the maternity ward of 48 hours or more,
- Female patient who has been informed about the study and has given her free, informed verbal consent to participate in the study.
Exclusion Criteria:
- Patients who have already participated in this study,
- Patients whose newborn(s) are hospitalised in neonatal units, neonatal intensive care units or neonatal resuscitation units,
- Patients who have given birth to three or more newborns (triplets or more),
- Patient whose newborn(s) has/have died,
- Patient unable to understand spoken or written French, making self-assessment impossible,
- Patient under guardianship, curatorship or placed under judicial protection,
- Patient not covered by the French social security system.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Intervention (additionnal psychological assessment)
The only intervention prompted by the research involves referring patients with an EPDS score of ≥10 and/or a positive response to item 10 of the scale ('has already thought about harming themselves') to a psychologist.
|
The only intervention resulting from the research consists of referring patients with an EPDS score ≥ 10 and/or a positive response to item 10 of this scale ('has already thought about harming themselves') to a psychologist.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Effect of visitor restriction levels implemented in maternity wards on mothers' postnatal depressive symptoms
時間枠:At discharge from hospitalization in the maternity ward, on average 48 hours
|
The incidence of depressive symptoms in the mother using the Edinburgh Postnatal Depression Scale (EPDS)
|
At discharge from hospitalization in the maternity ward, on average 48 hours
|
|
Effect of visitor restriction levels implemented in maternity wards on early indicators of newborn health.
時間枠:Until discharge from hospitalization in the maternity ward, on average 48 hours.
|
Neonatal weight change between birth and discharge from the maternity ward, reflecting the newborn's early health status.
|
Until discharge from hospitalization in the maternity ward, on average 48 hours.
|
協力者と研究者
捜査官
- 主任研究者:Noëllie FANTINATO, Midwife、Centre Hospitalier Annecy Genevois
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 24-08
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。